Breast Cancer Breakthroughs Highlights from ASCO 2023: HER3-DXd Trial

Breast Cancer Breakthroughs Highlights from ASCO 2023: NATALEE TrialПодробнее

Breast Cancer Breakthroughs Highlights from ASCO 2023: SONIA TrialПодробнее

Breast Cancer Breakthroughs Episode 3: Highlights from ASCO 2023Подробнее

ASCO 2023 Promising Results in Breast Cancer From NATALEE and PHERGainПодробнее

ASCO 2023 Breast Cancer Highlights with Prof Michael GnantПодробнее

Highlights from ASCO 2023Подробнее

Phase II trial of patritumab deruxtecan in metastatic breast cancerПодробнее

Breast Cancer Breakthroughs Highlights from ASCO 2023: PHERGAIN TrialПодробнее

ASCO 2023 highlights in breast cancer: NATALEE, monarchE, and PENELOPE-BПодробнее

Breast cancer highlights at ASCO 2022Подробнее

ASCO 2022: Metastatic Breast Cancer Drug Therapy RecapПодробнее

HER2 and HER3 Alterations as Therapeutic Targets of Increasing Significance in Solid TumorsПодробнее

Novel antibody-drug conjugates (ADCs) technologies for management of mBCПодробнее

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutate...Подробнее

DESTINY-Breast04 Study: T-DXd Breakthrough for HER2-Low Breast Cancer TreatmentПодробнее

Report Back from ASCO 2023: What’s the Latest News in Metastatic Breast Cancer?Подробнее

#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 studyПодробнее

Breast cancer highlights from the 2022 ASCO Annual Meeting | Harold BursteinПодробнее